ERBB3 and lung cancer: A locked nucleic acid-based HER3 antisense oligonucleotide (EZN-3920) decreased HER3 mRNA expression and tumor growth in breast and lung cancer models.[177] Table 7 summarizes the proposed mechanism of action of these promising novel strategies targeting HRG-mediated pathways under preclinical development.